close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.520 +0.020 (+0.57%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
Recursion (RXRX) Q3 2026 Earnings Call Transcript ↗
Cash runway now stretches into 2029 as clinical programs advance. 
Via The Motley Fool
Topics Earnings
News headline image
What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call ↗
Recursion Pharmaceuticals (NASDAQ:RXRX) reported updated clinical data for its investigational treatment for familial adenomatous polyposis, or FAP, along with early activity in its solid-tumor program... 
Via MarketBeat
Topics Artificial Intelligence Earnings
News headline image
Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Appoints Fred Hassan as Chair of the Board
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
1 Big Winner and 1 Loser From the Upcoming Anthropic IPO ↗
These two companies could move in different directions over the medium term. 
Via The Motley Fool
Topics Artificial Intelligence Initial Public Offering
News headline image
Next-Gen Biotech: RXRX, OCGN, SNTI, VIVS, ONCO Stocks to Watch
Via AB Newswire
Topics Artificial Intelligence
News headline image
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi’s development pipeline, with phase 1 clinical study currently planned to begin in 2027 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference ↗
Recursion Pharmaceuticals (NASDAQ:RXRX) outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley’s Global Healthcare Conference, with CEO and President Najat Khan emphasizing... 
Via MarketBeat
Topics Artificial Intelligence
News headline image
2 Beaten-Down Stocks to Avoid Right Now ↗
Don't catch a falling knife. 
Via The Motley Fool
News headline image
The Market Just Told You Which Layer Of AI Biology It Is Paying For
Issued on behalf of MindWalk Holdings Corp. 
From Market Updates
Via GlobeNewswire
News headline image
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates ↗
Recursion Pharmaceuticals (NASDAQ:RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and... 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Recursion (RXRX) Q2 2026 Earnings Call Transcript ↗
AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance. 
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
Recursion Pharmaceuticals Q2 Earnings Call Highlights ↗
Recursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense... 
Via MarketBeat
Topics Artificial Intelligence Earnings
News headline image
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
3 Stocks With the Most Upside by the End of 2026 ↗
Analysts remain optimistic that the market will view upcoming catalysts in a bullish light. 
Via The Motley Fool
Topics Workforce
News headline image
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
Company to host public Earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy? ↗
Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
2 Beaten-Down Stocks That Still Aren't Worth Buying ↗
Your hard-earned money would be better spent elsewhere. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
Two stocks that have fallen out of favor and one hot stock that was one of Thursday's biggest losers were on the Ark Invest founder's shopping list. 
Via The Motley Fool
Topics ETFs
News headline image
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? ↗
Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, and industry partnerships. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026? ↗
Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles. 
Via The Motley Fool
News headline image
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up? 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market ↗
Yes, many of the companies you've invested in also have their own stock portfolios. This is bullishness worth noting. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying ↗
These aren't for the faint of heart. 
Via The Motley Fool
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.